Lutfi Dogan1, Mehmet Ali Gulcelik2. 1. Department of General Surgery, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey. 2. Department of General Surgery, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey.
Abstract
BACKGROUND: It is well known that full segmentary resection can be performed using oncoplastic surgery (OPS) techniques, and the anatomic resection of the ductal system is possible. Therefore, the efficacy and safety of OPS should be investigated in the treatment of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: Patients who were diagnosed as pure DCIS and underwent surgical treatment and follow-up were retrospectively evaluated. Patients who underwent OPS and conventional breast-conserving surgery (BCS) were included in the study. The number of patients who required an intervention after the surgery and had a relapse during the follow-up period was determined in both groups. RESULTS: There were 45 patients in the OPS group and 138 patients in the BCS group. The mean tumor size was larger in patients in the OPS group (36 ± 12 mm vs. 24 ± 8 mm, p = 0.02). Six (12.7%) patients were reoperated in the OPS group. Of these, 4 were re-excisions and 2 were mastectomies. In this group, breast conservation was possible in 45 (95.7%) patients. Thirty-nine (27%) patients were reoperated in the BCS group. Of these, 23 were re-excisions, and 16 were mastectomies. In this group, breast conservation was possible in 126 (88.7%) patients (p = 0.02). There was no significant difference between the groups in terms of 5-year cumulative local recurrence rates. While the 5-year local recurrence-free survival rate was 93.3% in the OPS group, it was 90.8% in the BCS group. CONCLUSION: This study provided evidence that OPS can be used safely in the surgical treatment of DCIS by reducing re-excision and completion mastectomy rates compared to BCS.
BACKGROUND: It is well known that full segmentary resection can be performed using oncoplastic surgery (OPS) techniques, and the anatomic resection of the ductal system is possible. Therefore, the efficacy and safety of OPS should be investigated in the treatment of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: Patients who were diagnosed as pure DCIS and underwent surgical treatment and follow-up were retrospectively evaluated. Patients who underwent OPS and conventional breast-conserving surgery (BCS) were included in the study. The number of patients who required an intervention after the surgery and had a relapse during the follow-up period was determined in both groups. RESULTS: There were 45 patients in the OPS group and 138 patients in the BCS group. The mean tumor size was larger in patients in the OPS group (36 ± 12 mm vs. 24 ± 8 mm, p = 0.02). Six (12.7%) patients were reoperated in the OPS group. Of these, 4 were re-excisions and 2 were mastectomies. In this group, breast conservation was possible in 45 (95.7%) patients. Thirty-nine (27%) patients were reoperated in the BCS group. Of these, 23 were re-excisions, and 16 were mastectomies. In this group, breast conservation was possible in 126 (88.7%) patients (p = 0.02). There was no significant difference between the groups in terms of 5-year cumulative local recurrence rates. While the 5-year local recurrence-free survival rate was 93.3% in the OPS group, it was 90.8% in the BCS group. CONCLUSION: This study provided evidence that OPS can be used safely in the surgical treatment of DCIS by reducing re-excision and completion mastectomy rates compared to BCS.
Authors: Laleh G Melstrom; Kurt A Melstrom; Edward C Wang; Melissa Pilewskie; David J Winchester Journal: Am J Clin Oncol Date: 2010-10 Impact factor: 2.339
Authors: M J Silverstein; M D Lagios; S Groshen; J R Waisman; B S Lewinsky; S Martino; P Gamagami; W J Colburn Journal: N Engl J Med Date: 1999-05-13 Impact factor: 91.245
Authors: Francesca De Lorenzi; Julien Di Bella; Patrick Maisonneuve; Nicole Rotmensz; Giovanni Corso; Roberto Orecchia; Marco Colleoni; Giovanni Mazzarol; Mario Rietjens; Pietro Loschi; Stefano Marcelli; Paolo Veronesi; Viviana Galimberti Journal: Eur J Surg Oncol Date: 2018-04-24 Impact factor: 4.424
Authors: Bree R Eaton; Albert Losken; Derick Okwan-Duodu; David M Schuster; Jeffrey M Switchenko; Donna Mister; Karen Godette; Mylin A Torres Journal: Ann Surg Oncol Date: 2013-10-01 Impact factor: 5.344
Authors: R Jeevan; D A Cromwell; M Trivella; G Lawrence; O Kearins; J Pereira; C Sheppard; C M Caddy; J H P van der Meulen Journal: BMJ Date: 2012-07-12